.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Harvard Business School
Accenture
QuintilesIMS
Boehringer Ingelheim
Cantor Fitzgerald
McKinsey
Moodys
Chubb
AstraZeneca

Generated: June 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,551,148

« Back to Dashboard

Claims for Patent: 4,551,148

Title: Vaginal delivery systems and their methods of preparation and use
Abstract:Systems and their methods of preparation and use that release an active agent in a controlled manner for an extended period in a vaginal cavity environment. The systems are capable of delivering the active agent for periods greater than three hours at a predictable rate to a predetermined site, the vaginal cavity.
Inventor(s): Riley, Jr.; Thomas C. (Manchester, MO), Tharp; Charles P. (Belleville, IL), Lapka; Galen G. (St. Louis, MO)
Assignee: KV Pharmaceutical Company (St. Louis, MO)
Application Number:06/663,145
Patent Claims: 1. Vaginal delivery systems which are bioadherent to the vaginal surfaces and which release an active agent in a controlled manner for at least three hours to a receptor site, site of action, site of absorption, or site of use consisting essentially of liquid or semi-solid adjacent unit cells having common lipoidal external phases, nonlipoidal internal phases and emulsifiers.

2. The vaginal delivery systems of claim 1 wherein said phases form a liquid or semi-solid.

3. The vaginal delivery systems of claim 1 wherein said phases form to comprise an emulsion, emulsion/dispersion, double emulsion, suspension within an emulsion or mixture.

4. The vaginal delivery systems of claim 1 wherein at least a portion of the active agent is contained in said nonlipoidal phases.

5. The vaginal delivery systems of claim 1 wherein the active agent comprises nonoxynol-9.

6. The vaginal delivery systems of claim 1 wherein the active agent comprises nystatin.

7. The vaginal delivery systems of claim 1 wherein the active agent comprises a pH buffer.

8. The vaginal delivery systems of claim 1 wherein said nonlipoidal phases comprise at least 70% by volume of said systems.

9. The vaginal delivery systems of claim 1 wherein said nonlipoidal phases comprise either water, glycerine or a combination thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
US Army
Queensland Health
Teva
Merck
Chubb
Federal Trade Commission
US Department of Justice
QuintilesIMS
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot